Level Four Advisory Services’s Acadia Pharmaceuticals ACAD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
– Sell
-17,565
Closed -$366K – 778
2023
Q3
$366K Buy
+17,565
New +$477K 0.02% 529

Other funds holding ACAD

Level Four Advisory Services's ACAD Position: Q4 2023 in Review

Level Four Advisory Services sold out of Acadia Pharmaceuticals (ACAD) in Q4 2023, closing a stake of 17,565 shares — an estimated $366K sold.

Level Four Advisory Services first reported a position in ACAD in Q3 2023 and held it in 1 quarter. The position peaked at $366K in Q3 2023. 276 funds tracked by Wall St. Rank hold ACAD as of Q4 2023.

  • Level Four Advisory Services reported no remaining Acadia Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Level Four Advisory Services sold 17,565 Acadia Pharmaceuticals shares in Q4 2023, an estimated $366K.
  • Level Four Advisory Services first reported a position in Acadia Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Level Four Advisory Services's Acadia Pharmaceuticals position peaked at $366K in Q3 2023.
  • 276 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2023.

Based on Level Four Advisory Services's 13F filing for Q4 2023, filed 8 Feb 2024.